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Sirtuins represent a promising new class of conserved histone deacetylases, originally
identiﬁed in yeast. The activity of the sirtuin (SirT) family – made up of seven members
(SirT1-7) – is NAD+ dependent. Sirtuins target a wide range of cellular proteins in nucleus,
cytoplasm, and mitochondria for post-translational modiﬁcation by acetylation (SirT1, 2, 3,
and 5) or ADP-ribosylation (SirT4 and 6). Sirtuins regulate responses to stress and ensure
that damaged DNA is not propagated, thus contrasting the accumulation of mutations.
To date, sirtuins have emerged as potential therapeutic targets for treatment of human
pathologies such as metabolic, cardiovascular and neurodegenerative diseases, and can-
cer. SirT1 is the founding member of this class of enzymes and is currently the best known
of the group. SirT1 acts in various cellular processes, deacetylating both chromatin and non-
histone proteins, and its role in cancer and aging has been extensively studied. SirT1 may
play a critical role in tumor initiation and progression as well as drug resistance by block-
ing senescence and apoptosis, and by promoting cell growth and angiogenesis. Recently,
growing interest in sirtuin modulation has led to the discovery and characterization of small
molecules able tomodify sirtuin activity.The present review highlights SirTmechanism(s) of
action and deregulation in cancer, focusing on the therapeutic potential of SirT modulators
both in cancer prevention and treatment.
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INTRODUCTION
Epigenetic modiﬁcations play an important role in regulating gene
expression, lifespan, and tumorigenesis. In particular, acetylation
regulates a wide variety of cellular functions. Class III histone
deacetylases (HDACs), also known as sirtuins, are the silent infor-
mation regulator 2 (Sir2) family of proteins. Unlike other HDACs,
sirtuins are NAD+-dependent deacetylases, not modulated by
inhibitors of class I, II, and IV HDACs. The deacetylase activ-
ity of sirtuins is controlled by the cellular [NAD+]/[NADH]
ratio, where NAD+ works as an activator, while nicotinamide
and NADH act as inhibitors. Expressed from bacteria to humans
(Vaquero, 2009), sirtuins seem to preferentially target non-histone
proteins, although little is currently known about target speci-
ﬁcity and selectivity. Two reactions may be catalyzed by sirtuins:
deacetylation and ADP-ribosylation. In both reactions, the cleav-
age of NAD+ is the initial chemical step. Sirtuins (SirT1, SirT2,
SirT3, SirT5, and SirT7) catalyze a deacetylation reaction on lysine
residues of target proteins, using NAD+ as cofactor and releas-
ing nicotinamide with the production of 2′-O-acetyl-ADP ribose.
In contrast, SirT4 and SirT6 catalyze an ADP-ribosylation reac-
tion, in which ADP-ribosyl moiety is transferred to the substrate
(Yamamoto et al., 2007).
CATALYTIC DOMAIN OF SIRTUINS
Eachmember of the sirtuin family contains a highly conserved core
domain consisting of anNAD+ binding site and a catalytic domain
(Alcaín and Villalba, 2009). Human SirT2 consists of two globular
domains: one large andone small. In the large domain,with aRoss-
mann fold, six β-strands form a parallel β-sheet and six α-helices.
The small domain is composed of a helical and a zinc-binding
module. The active site is located at the interface between the large
and small domains, with a binding site for NAD+. The NAD+-
binding pocket can be divided into three spatially distinct regions:
the A site, with afﬁnity for adenine–ribose, the B site, with afﬁnity
for nicotinamide–ribose, and the C site, which binds NAD+. In
the presence of an acetyl-lysine substrate, the NAD+-bound B site
can undergo a conformational change, bringing nicotinamide in
proximity to the C site, where it can be cleaved. The ADP ribose
product returns to the B site, allowing deacetylation. The C site
is the binding site for free nicotinamide. At high concentrations
it may occupy the site and block the conformational change of
NAD+ (North and Verdin, 2004).
SIRTUIN FAMILY
The mammalian sirtuin family comprises seven proteins (SirT1-
7). These proteins differ in cellular localization, activity, and func-
tion, and are subdivided into four classes (Alcaín and Villalba,
2009; Table 1). SirT1, the closest to yeast Sir2 in terms of sequence,
is a proto-member of the family. SirT1 mediates heterochromatin
formation through deacetylation of K26 on histone H1, K9 on
histone H3, and K16 on histone H4. SirT1 is also involved in the
deacetylation of non-histone proteins, which can be divided into
three groups: (i) transcription factors (p53, FOXO, E2F1, BCL6,
p73, Rb, and others); (ii) DNA repair proteins; (iii) signaling fac-
tors. Due to its ability to deacetylate a variety of substrates, SirT1
is involved in a broad range of physiological functions, includ-
ing control of gene expression, metabolism, tumorigenesis, and
aging.
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Table 1 | Diversity of human sirtuins.
Classes Enzymatic
activity
Targets and
Substrate
Localization Function Involvement
in cancer
Deacetylase p53, FOXO,
MyoD, Ku70,
PPARγ
NFκB, PCAF,
H3K9, H3KI4,
Nuclear/
cytoplasmatic
Glucose
metabolism,
differentiation,
neuroprotection,
insulin secretion
Acute myeloid
leukemia, colon,
bladder, prostate,
glioma, nonmalig-
nant skin, ovarian
I Deacetylase α-Tubulin
FOXO
Nuclear/
cytoplasmatic
Cell-cycle control,
tubulin
deacetylation
Glioma
Deacetylase GHD complex
1, AceCS2
Mitochondrial ATP-production,
regulation of
mitochondrial
proteins
deacetylation,
fatty-acid oxidation
Breast cancer
II ADP-
ribosyl-
transferase
GHD, ANT Mitochondrial Insulin secretion Breast cancer
III Deacetylase CPSI Mitochondrial Urea cycle Pancreatic,
breast cancer
IV Deacetylase
ADP-
ribosyl-
transferase
Hif1α, helicase
NFκB, DNA
polimerasi β
Nuclear Telomeres and
telomeric
functions, DNA
repair
Colon,
breast cancer
Deacetylase RNA
polymerase
type 1, ElA
SMAD6
Nuclear RNA pol I
transcription
Breast cancer
Human SirT2 co-localizes with microtubules in cytoplasm.
Thus, knockdown of SirT2 results in tubulin hyperacetylation.
SirT2 is also able to bind FOXO3a, reducing its acetylation
levels.
SirT3 is localized in mitochondrial inner membrane, and is
activated by caloric restriction. SirT4 is also mitochondrial, but
no NAD+-dependent deacetylase activity has so far been detected
for this sirtuin. SirT4 uses NAD+ for ADP-ribosylation of gluta-
mate dehydrogenase, resulting in inhibition of insulin secretion
and enzymatic activity of β-cells. The third mitochondrial sirtuin,
SirT5, is localized in the inter-membrane space and can deacety-
late cytochrome c. The last two sirtuins, SirT6 and SirT7, have
recently been characterized. SirT6 exerts an NAD+-dependent
histone H3 K9 deacetylase action able to modulate telomeric
chromatin functions (Alcaín and Villalba, 2009). SirT6 has a role
in genome stability. In mammalian cells subjected to oxidative
stress, SirT6 is recruited on DNA double-strand breaks (DSB) and
stimulates repair through both homologous and non-homologous
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end-joining recombination. Moreover, some results indicate that
SirT6 is physically associated with poly [adenosine diphosphate
(ADP)-ribose] polymerase 1 (PARP1). The amount of SirT6–
PARP1 complexes increase after DNA damage. PARP1 is mono-
ADP-ribosylated on lysine residue K521, thus increasing PARP1
activity and enhancing DSB repair under oxidative stress (Mao
et al., 2011). SirT7 is a predominantly nucleolar protein asso-
ciated with active rRNA genes (rDNA), where it interacts with
RNA polymerase I and histones (Alcaín and Villalba, 2009). SirT7
does not seem to have any NAD+-dependent activity. Other func-
tional characteristics of SirT6 and SirT7 remain to be further
elucidated.
Some sirtuins may relocalize depending on cell or tissue type,
developmental stage, stress condition, and metabolic status, sug-
gesting that their localization is important for regulating function
(McGuinness et al., 2011).
SIRTUINS AND GENOME STABILITY
Some sirtuins (SirT1, 2, 3, 6) are linked to chromatin regula-
tion, as they are responsible for the regulation of two histone
post-translational modiﬁcations crucial for chromatin structure:
acetylation of K16 and K9 on histone H4 and H3 respectively
(McGuinness et al., 2011).
SirT1 is responsible for heterochromatin formation by a
deacetylation process. Histone deacetylation can in turn facili-
tate histone methylation, thus enhancing global transcriptional
repression. SirT1 has no effect on H3K4 methylation (a marker
of open chromatin) and promotes H3K9 tri-methylation through
its involvement with the histone methyltransferase Suv39H1 (Liu
et al., 2009; Bosch-Presegue and Vaquero, 2011).
SirT2 and SirT3 are responsible for regulation of H4K16 acety-
lation. Deacetylation occurs speciﬁcally during cell-cycle in G2/M
transition, in particular when SirT2 is shuttled to the nucleus
(Shogren-Knaak et al., 2006). The mechanism of SirT3 is more
complex. Although SirT3 is localized in mitochondria, its feeble
nuclear expression is probably responsible for deacetylation of
H4K16ac and H3K9ac in some settings (McGuinness et al., 2011).
The ﬁnding that SirT3 knockdown does not lead to global H4K16
hyperacetylation suggests that its action occurs in limited regions
of the genome.
Recently, SirT6 has been attributed with deacetylase activity
(McGuinness et al., 2011), since it modulates acetylation of K9
and K56 on histone H3.
SIRTUINS AND CANCER
Interest in sirtuins has grown in the last decade, mainly because of
their critical role in different biological processes, such as regula-
tion of gene expression, control of metabolic processes, apoptosis
and cell survival, DNA repair, development, neuro-protection,
and inﬂammation. Sirtuins control many vital functions and
are involved in several pathologies such as metabolic diseases,
neurodegenerative disorders, and cancer.
SirT1 has been shown to be signiﬁcantly up-regulated in dif-
ferent types of cancer including acute myeloid leukemia (AML),
prostate, colon, and skin cancers.
Given that only SirT1 and SirT2 seem to control levels of H4K16
acetylation in many settings, and that only SirT1 is proven to
be altered in certain cancers, H4K16ac loss in cancer has been
correlated with SirT1 deregulated activity.
Nevertheless, SirT1 seems to play contradictory roles, both
as tumor suppressor or tumor promoter (Deng, 2009; Bosch-
Presegue and Vaquero, 2011). The initial evidence that SirT1 acts
as tumor promoter derives from its repressive effect on tumor
suppressor p53 (Deng, 2009). By interacting physically with p53,
SirT1 blocks its functions through deacetylation at the C-terminal
K382 residue (Vaziri et al., 2001). Moreover, SirT1 overexpression
in cancer represses p53-dependent cell-cycle arrest and apoptosis
in response to DNA damage and oxidative stress. DNA damage-
induced acetylation of p53 leads to its activation. In response to
damage, SirT1 binds to and deacetylates p53, thus reducing its
functional and transcriptional activities. Overexpression of SirT1
disrupts p53-dependent pathways, resulting in a signiﬁcant reduc-
tion in the cell’s ability to respond to stress and DNA damage.
In contrast, the inhibition of SirT1 potentiates p53-dependent
apoptosis (Deng, 2009; Rahman and Islam, 2011). These ﬁnd-
ings underline the involvement of SirT1 in tumorigenesis, given
that SirT1 overexpression may increase the risk of cancer in mam-
mals by inhibiting p53 and potentially other tumor suppressor
genes, including FOXO family members, p73, Rb, and several
others.
In contrast, several studies have suggested that SirT1 also
has a tumor suppressor role. Decreased SirT1 levels have been
reported for glioma, bladder, prostate, and ovarian cancers. Fur-
thermore, some studies have suggested that SirT1 overexpression
in APC−/+ mice reduces rather than increases colon cancer for-
mation (Firestein et al., 2008). This action seems to be caused
by SirT1 deacetylation of β-catenin, which promotes cytoplas-
mic localization of the nuclear-localized oncogenic form of β-
catenin. In addition, in SirT1-deﬁcient mice, embryos die at mid-
dle gestation stages, displaying increased acetylation of H3K9 and
H4K16, reduced chromosome condensation and aberrant mito-
sis (Firestein et al., 2008; Deng, 2009). SirT1 deﬁciency also causes
reduced DNA double-strand break repair and radiation sensitivity
(Wang et al., 2008). It has also been suggested that SirT1 plays a
role as tumor suppressor by regulating c-Myc. c-Myc binds to and
induces SirT1. This interaction results in decreased c-Myc sta-
bility, compromising its transformational capability. These data
provide strong evidence for a tumor suppressor role of SirT1
in these settings. Importantly, it still seems possible that the
expression level and activity of SirT1 may modulate a delicate
balance between suppression and promotion of oncogenesis, thus
displaying dual dependence on its spatial and temporal distribu-
tion and stage of tumorigenesis (Bosch-Presegue and Vaquero,
2011). A potential tumor suppressor role has also been pro-
posed for the other human sirtuins (McGuinness et al., 2011).
This hypothesis is supported by several ﬁndings such as the
reduction of SirT2 in a large number of human brain tumor
cell lines, and its involvement in cell-cycle progression. SirT3
is the only mitochondrial sirtuin implicated in tumorigenesis.
Its reduction in several cancers leads to an increase in ROS
(reactive oxygen species) production, which results in enhanced
tumor growth (Kim et al., 2010). SirT5 overexpression has been
found in a study of pancreatic cancer (Ouaïssi et al., 2008).
Recently, a role for SirT6 and SirT7 in tumorigenesis has also
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been proposed. SirT6 might be involved as a result of its con-
trol of the NFκB pathway and DNA double-strand repair. SirT7,
whose expression inversely correlates with the tumorigenic poten-
tial in several murine cell lines (Vakhrusheva et al., 2008), dis-
plays increased expression levels in breast cancer (Ashraf et al.,
2006).
Following these rationals, tumors with deregulated expression
or function of sirtuins may beneﬁt from an approach based on the
use of SirT inhibitors.
SIRTUIN AND AGING DISEASES
Sirtuins are believed to be involved inmetabolic diseases, neurode-
generation, and aging.
It is well known that overexpression of Sir2 (or its orthologs)
can extend organism lifespan in a wide range of lower eukary-
otes (Bosch-Presegue and Vaquero, 2011). Sir2 function is often
correlated to caloric restriction. The link between the role of sir-
tuins, caloric restriction, and longevity was ﬁrst described in S.
cerevisiae. In yeast, caloric restriction leads to increased replica-
tive lifespan. Lifespan extension has not been observed in yeast
lacking Sir2 (Lin et al., 2000). Currently, the role of sirtuins in
the regulation of mammalian lifespan is still unclear. However,
considering that sirtuins are an evolutionary conserved family of
proteins, it is fair to speculate on their role in the modulation of
aging-related processes in higher organisms (Westphal et al., 2007;
Brooks and How, 2009). In humans, the aging process is associ-
ated with telomere erosion. SirT1 and SirT6 have a role in both
the maintenance of telomeres and their function, as well as the
aging process. Recent studies have demonstrated that reduction
or removal of SirT6 results in telomere dysfunction and end-to-
end chromosomal fusions. Symptoms displayed in the absence
of SirT6 are similar to those caused by a premature aging dis-
ease, known as Werner’s syndrome. To date, little is known about
other sirtuins, but no evidence suggests their involvement with
telomere function, formation, and stability (Westphal et al., 2007;
McGuinness et al., 2011). Recently, SirT1 has been shown to pro-
mote replicative senescence in response to chronic oxidative stress,
by upregulation of the p19ARF senescence regulator, which in turn
positively regulates p53 via inhibition of MDM2, a protein medi-
ating p53 degradation (Chua et al., 2005). This effect seems to
be in contrast to Sir2 function in yeast, which extends replicative
lifespan.
Many studies have demonstrated that the pathogenesis of neu-
rodegenerative diseases includes broad changes and involvement
of multiple biochemical pathways. Sirtuins play a critical role in
several models of neurodegenerative diseases. Many reports sup-
port the role of SirT1 in axonal protection from damage in animal
models of Wallerian degenerative disease (Parkinson’s disease;
Araki et al., 2004; McGuinness et al., 2011; Rahman and Islam,
2011). SirT1 overexpression also protects against Alzheimer’s and
Huntington’s disease as well as amyotrophic lateral sclerosis. In
models of Huntington’s disease, SirT1 activation reduces cell death
by inhibition of NFκB signaling. Alzheimer’s disease is also related
to sirtuin action given that SirT1 overexpression in the brain of
mice reduces β-Amyloid production and the formation of plaques.
The β-Amyloid peptide generates protein aggregates (plaques) in
the brain of patients (Outiero et al., 2008). Recent studies also
suggest that SirT1 may beneﬁt learning and memory by activat-
ing the gene for brain-derived neurotrophic factor (Gao et al.,
2010).
SIRTUIN MODULATORS
Sirtuins play a key role in several pathologies. Recently, a great
deal of research interest has been focused on the identiﬁcation of
small chemical compounds that modulate these proteins. To date,
many inhibitors of sirtuins have been proposed for therapy against
neurodegenerative diseases and cancer (Alcaín andVillalba, 2009).
In recent years a number of inhibitors have been discovered and
characterized. In addition to nicotinamide, the physiologic sirtuin
inhibitor, some speciﬁc inhibitors have been proposed, includ-
ing splitomicin and its analogs, tenovins, AGK2, sirtinol, suramin,
the indole derivative EX-257, cambinol, salermide, and UVI5008
(Table 2).
Table 2 | Sirtuin modulators.
Structure Name Target
Nicotinamide SirT1-2
AGK2 SirT2
Cambinol SirT1-2
Salermide SirT1-2
EX-527 SirT1
Splitomicin Sir2
Suramin SirT1-2-5
UVI5008 SirT1-2
Sirtinol SirT2
Tenovins SirT1
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Splitomicin and its derivatives were discovered in a screening
for inhibitors of yeast Sir2. While splitomicin did not act very
efﬁciently against human sirtuins, a series of its analogs with a
different orientation of the β-phenyl group were developed and
characterized for their activity on SirT2 (Bedalv et al., 2001;Neuge-
bauer et al., 2008). Sirtinol is mainly an inhibitor of the yeast Sir2
and human SirT2 (Grozinger et al., 2001). Its inhibitory effect on
growth has been described in human breast, lung, and prostate
cancer cells, though using a high micromolar range.
Another potent and selective inhibitor of SirT2 is AGK2 with
IC50 of 3.5μM. It was demonstrated that the inhibition of SirT2
protects against dopaminergic cell death in a Drosophila model of
Parkinson’s disease (Outeiro et al., 2007).
Suramin is a potent inhibitor of many sirtuins: SirT1 with IC50
of 297 nM, SirT2 with IC50 of 1.15μM, and SirT5 with IC50 of
22μM. However, its reported neurotoxicity limits therapeutic use
(Schuetz et al., 2007; Trapp et al., 2007).
Cambinol and salermide (Heltweg et al., 2006; Lara et al., 2009)
are reported as inhibitors of SirT1 and SirT2. Cambinol shows
the most potent activity against Burkitt lymphoma cell lines by a
mechanism involving BCL6 acetylation. Salermide induces apop-
tosis in cancer cells in a p53-independent manner. The indole
derivative, EX-527, is a cell-permeable, selective inhibitor of SirT1
(IC50 = 98 nM). Treatment with EX-527 dramatically increases
acetylation atK382of p53 afterDNAdamage induction in primary
human mammary epithelial cells and several cell lines (Solomon
et al., 2006). The direct interaction between SirT1 and p53 high-
lights potential SirT1 involvement in p53 functions, including
differentiation, DNA repair, and aging. Currently, EX-527 is in
phase 1 clinical trials for the treatment of Huntington’s disease.
In preclinical studies this inhibitor was shown to reduce neuronal
death.
The only SirT inhibitors that have been tested in cancer mice
models are cambinol, tenovins, andUVI5008. Tenovins, a family of
small-molecule inhibitors, are able to inhibit SirT1 at single-digit
micromolar concentration and prevent tumor growth in vivo in a
p53-dependent manner as single agents. Tenovins have a poten-
tial therapeutic interest for the development of new drugs that act
against tumor cells overexpressing SirT1 (Lain et al., 2008).
UVI5008 has recently been reported as a novel epigenetic mod-
iﬁer able to inhibit simultaneously histone deacetylases, sirtuins,
and DNA methyltransferases. This compound induces cancer cell-
selective death in several human models. Importantly, UVI5008
action is independent of p53, Bcl-2-modifying factor (BMF),
andTNF-related apoptosis-inducing ligand (TRAIL), affecting the
growth of tumor cells deﬁcient or mutated for these factors. This
ﬁndingpotentiates its application in therapybyovercomingpoten-
tial drug resistance limits. The simultaneous modulation of three
classes of epigenetic enzymes offers a promising strategy for apply-
ing a single drug exerting multiple-interventions against cancer
(Nebbioso et al., 2011).
Phenol derivates, including quercetin, piceatannol, and resver-
atrol, were shown to have SirT1-activating properties. The most
potent activator of the three is resveratrol, a polyphenol found in
grapes, and grape products. However, its activity is still debated.
Given that the activation of SirT1 by resveratrol requires the use
of peptides conjugated with a non-physiological ﬂuorophore and
that no activation is observed when peptides lacking this ﬂu-
orophore are used, other technical approaches are necessary to
establish its effective modulation of SirT1 (Borra et al., 2005).
CONCLUSION AND PERSPECTIVES
Sirtuins inﬂuence several cellular processes. Growing evidence has
recently underlined their involvement in many diseases. Although
SirT1 has been extensively researched a better understanding of its
involvement in pathogenesis is required. Many questions remain
to be addressed, such as the role of the other sirtuins and their
function. Further research is needed to provide clearer perspec-
tives. The development of potent sirtuin modulators may revert
the disease process and possibly extend healthy human lifespan.
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